Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer
Background This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlate...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2012-05, Vol.19 (5), p.1707-1712 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1712 |
|---|---|
| container_issue | 5 |
| container_start_page | 1707 |
| container_title | Annals of surgical oncology |
| container_volume | 19 |
| creator | Kong, Sun-Young Han, Mi Hwa Yoo, Heon-Jong Hwang, Jong Ha Lim, Myong Cheol Seo, Sang-Soo Yoo, Chong-Woo Kim, Jae-Hoon Park, Sang-Yoon Kang, Sokbom |
| description | Background
This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.
Methods
We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.
Results
The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3–222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test,
P
= 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (
P
= 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (
P
= 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (
P
= 0.003 and 0.033).
Conclusions
Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information. |
| doi_str_mv | 10.1245/s10434-011-1943-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1009549795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2660377881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-3922f731947867363432720c8166de3d8d255423c2232fa71ae79ea73a072a043</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBcJePGymmTysXuU0tpCoQX1vMTdad2yzdZkt-C_N6VVRPCShOSZdyYPIdec3XMh1UPgTIJMGOcJzyQk6oT0uYo3Uqf8NJ6ZTpNMaNUjFyGsGeMGmDonPcFTAK3TPlk8o-82dDKSdIY7rGkVqHV06krcYlxcSxe-WbkmtFVBx7ZoG08rR0fbqn3HurI1ne-sr2LN0LoC_SU5W9o64NVxH5DX8ehlOElm86fp8HGWFGBEm0AmxNJAHNuk2oAGCcIIVqRc6xKhTEuhlBRQCAFiaQ23aDK0BiwzwsZvD8jdIXfrm48OQ5tvqlBgXVuHTRdyzlimZGYyFdHbP-i66byL00WKg9RCSYgUP1CFb0LwuMy3vtpY_xmhfK87P-jOo-58rzvfJ98ck7u3DZY_Fd9-IyAOQIhPboX-d-v_Ur8A8nyGlQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013462543</pqid></control><display><type>article</type><title>Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Kong, Sun-Young ; Han, Mi Hwa ; Yoo, Heon-Jong ; Hwang, Jong Ha ; Lim, Myong Cheol ; Seo, Sang-Soo ; Yoo, Chong-Woo ; Kim, Jae-Hoon ; Park, Sang-Yoon ; Kang, Sokbom</creator><creatorcontrib>Kong, Sun-Young ; Han, Mi Hwa ; Yoo, Heon-Jong ; Hwang, Jong Ha ; Lim, Myong Cheol ; Seo, Sang-Soo ; Yoo, Chong-Woo ; Kim, Jae-Hoon ; Park, Sang-Yoon ; Kang, Sokbom</creatorcontrib><description>Background
This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.
Methods
We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.
Results
The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3–222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test,
P
= 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (
P
= 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (
P
= 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (
P
= 0.003 and 0.033).
Conclusions
Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-011-1943-5</identifier><identifier>PMID: 21833668</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; Carboplatin - administration & dosage ; Carcinoma, Ovarian Epithelial ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Neoplasm Grading ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial - blood ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - pathology ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Paclitaxel - administration & dosage ; Prognosis ; Proteins - analysis ; Serum ; Surgery ; Surgical Oncology ; Translational Research and Biomarkers</subject><ispartof>Annals of surgical oncology, 2012-05, Vol.19 (5), p.1707-1712</ispartof><rights>Society of Surgical Oncology 2011</rights><rights>Society of Surgical Oncology 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-3922f731947867363432720c8166de3d8d255423c2232fa71ae79ea73a072a043</citedby><cites>FETCH-LOGICAL-c372t-3922f731947867363432720c8166de3d8d255423c2232fa71ae79ea73a072a043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-011-1943-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-011-1943-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21833668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kong, Sun-Young</creatorcontrib><creatorcontrib>Han, Mi Hwa</creatorcontrib><creatorcontrib>Yoo, Heon-Jong</creatorcontrib><creatorcontrib>Hwang, Jong Ha</creatorcontrib><creatorcontrib>Lim, Myong Cheol</creatorcontrib><creatorcontrib>Seo, Sang-Soo</creatorcontrib><creatorcontrib>Yoo, Chong-Woo</creatorcontrib><creatorcontrib>Kim, Jae-Hoon</creatorcontrib><creatorcontrib>Park, Sang-Yoon</creatorcontrib><creatorcontrib>Kang, Sokbom</creatorcontrib><title>Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.
Methods
We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.
Results
The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3–222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test,
P
= 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (
P
= 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (
P
= 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (
P
= 0.003 and 0.033).
Conclusions
Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Cohort Studies</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Glandular and Epithelial - blood</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - pathology</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Prognosis</subject><subject>Proteins - analysis</subject><subject>Serum</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Translational Research and Biomarkers</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBcJePGymmTysXuU0tpCoQX1vMTdad2yzdZkt-C_N6VVRPCShOSZdyYPIdec3XMh1UPgTIJMGOcJzyQk6oT0uYo3Uqf8NJ6ZTpNMaNUjFyGsGeMGmDonPcFTAK3TPlk8o-82dDKSdIY7rGkVqHV06krcYlxcSxe-WbkmtFVBx7ZoG08rR0fbqn3HurI1ne-sr2LN0LoC_SU5W9o64NVxH5DX8ehlOElm86fp8HGWFGBEm0AmxNJAHNuk2oAGCcIIVqRc6xKhTEuhlBRQCAFiaQ23aDK0BiwzwsZvD8jdIXfrm48OQ5tvqlBgXVuHTRdyzlimZGYyFdHbP-i66byL00WKg9RCSYgUP1CFb0LwuMy3vtpY_xmhfK87P-jOo-58rzvfJ98ck7u3DZY_Fd9-IyAOQIhPboX-d-v_Ur8A8nyGlQ</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Kong, Sun-Young</creator><creator>Han, Mi Hwa</creator><creator>Yoo, Heon-Jong</creator><creator>Hwang, Jong Ha</creator><creator>Lim, Myong Cheol</creator><creator>Seo, Sang-Soo</creator><creator>Yoo, Chong-Woo</creator><creator>Kim, Jae-Hoon</creator><creator>Park, Sang-Yoon</creator><creator>Kang, Sokbom</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer</title><author>Kong, Sun-Young ; Han, Mi Hwa ; Yoo, Heon-Jong ; Hwang, Jong Ha ; Lim, Myong Cheol ; Seo, Sang-Soo ; Yoo, Chong-Woo ; Kim, Jae-Hoon ; Park, Sang-Yoon ; Kang, Sokbom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-3922f731947867363432720c8166de3d8d255423c2232fa71ae79ea73a072a043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Cohort Studies</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Glandular and Epithelial - blood</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - pathology</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Prognosis</topic><topic>Proteins - analysis</topic><topic>Serum</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Translational Research and Biomarkers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kong, Sun-Young</creatorcontrib><creatorcontrib>Han, Mi Hwa</creatorcontrib><creatorcontrib>Yoo, Heon-Jong</creatorcontrib><creatorcontrib>Hwang, Jong Ha</creatorcontrib><creatorcontrib>Lim, Myong Cheol</creatorcontrib><creatorcontrib>Seo, Sang-Soo</creatorcontrib><creatorcontrib>Yoo, Chong-Woo</creatorcontrib><creatorcontrib>Kim, Jae-Hoon</creatorcontrib><creatorcontrib>Park, Sang-Yoon</creatorcontrib><creatorcontrib>Kang, Sokbom</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kong, Sun-Young</au><au>Han, Mi Hwa</au><au>Yoo, Heon-Jong</au><au>Hwang, Jong Ha</au><au>Lim, Myong Cheol</au><au>Seo, Sang-Soo</au><au>Yoo, Chong-Woo</au><au>Kim, Jae-Hoon</au><au>Park, Sang-Yoon</au><au>Kang, Sokbom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>19</volume><issue>5</issue><spage>1707</spage><epage>1712</epage><pages>1707-1712</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.
Methods
We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.
Results
The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3–222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test,
P
= 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (
P
= 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (
P
= 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (
P
= 0.003 and 0.033).
Conclusions
Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>21833668</pmid><doi>10.1245/s10434-011-1943-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2012-05, Vol.19 (5), p.1707-1712 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1009549795 |
| source | MEDLINE; Springer Online Journals Complete |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - blood CA-125 Antigen - blood Carboplatin - administration & dosage Carcinoma, Ovarian Epithelial Cohort Studies Disease-Free Survival Female Humans Medicine Medicine & Public Health Middle Aged Multivariate Analysis Neoplasm Grading Neoplasm Staging Neoplasms, Glandular and Epithelial - blood Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - pathology Oncology Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Prognosis Proteins - analysis Serum Surgery Surgical Oncology Translational Research and Biomarkers |
| title | Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T17%3A45%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20HE4%20Level%20is%20an%20Independent%20Prognostic%20Factor%20in%20Epithelial%20Ovarian%20Cancer&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Kong,%20Sun-Young&rft.date=2012-05-01&rft.volume=19&rft.issue=5&rft.spage=1707&rft.epage=1712&rft.pages=1707-1712&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-011-1943-5&rft_dat=%3Cproquest_cross%3E2660377881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1013462543&rft_id=info:pmid/21833668&rfr_iscdi=true |